[Progress in development of new antischistosomal drugs in recent years].
It is estimated that 200 million people have suffered the infection with schistosomes in the world. The fact that treatment of schistosomiasis only relies on a single drug praziquantel does not adapt to the demand. Although praziquantel exhibits excellent therapeutic efficacy, it shows no preventive action to the infection. Therefore, development of new anti-schistosomal drugs has been received serious attention. In this paper the recent development of new antischistosomal drugs such as oxadiazole-2-oxides, mefloquine, etc. has been reviewed, and the process of their development and anti-schistosomal properties recounted.
Xiao
Shu-Hua
SH
National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Shanghai 200025, China.
D000818:Animals; D015767:Mefloquine / Q000494:pharmacology; D010069:Oxadiazoles / Q000494:pharmacology; D011223:Praziquantel / Q000494:pharmacology; D012547:Schistosoma / Q000187:drug effects; D012556:Schistosomicides
D010069:Oxadiazoles; D012556:Schistosomicides; D011223:Praziquantel; D015767:Mefloquine